Organigram signs supply agreement with Lotteries & Manitoba Liquor

Organigram signs supply agreement with Manitoba Liquor & Lotteries

Organigram Holdings Inc. (TSX VENTURE: OGI) (OTCQB: OGRMF), the parent company of Organigram Inc. (the”Company” or”Organigram”), a leading licensed producer of medical marijuana based in Moncton, New Brunswick, is very happy to announce that it’s been approved as a provider of cannabis for the province of Manitoba.

Organigram Holdings Inc. (CNW Group/OrganiGram)

“We are proud to work with MBLL to provide residents of Manitoba a choice of high-quality cannabis products,” says Tim Emberg, Organigram Vice President of Sales and Commercial Operations. “As we expand our own nationwide footprint, we anticipate working with retailers in Manitoba to deliver an exceptional customer experience.”

Organigram continues to expand its national presence

The agreement with MBLL represents another milestone in the corporation’s strategic plan to work with regulators and vendors throughout the country.

Organigram has signed two previous memorandums of understanding including an MOU with the Government of New Brunswick (GNB), signed in 2017 to provide a minimum of 5-million grams of cannabis annually worth an estimated retail value of between $40-million to $60-million annually.

In 2018, the Company also signed an MOU with the Prince Edward Island Liquor Control Commission for the supply of cannabis into the state’s adult recreational market. That agreement is estimated to have a retail value of between $8-million to $12-million each year.

“We are very happy to continue to build — and formalize — positive, effective working relationships with partners throughout the country and help ensure the success of new adult-use recreational cannabis markets in each of these areas,” says Greg Engel, Organigram CEO.

For more information, see www.Organigram.ca

About Organigram Holdings Inc..

Organigram Holdings Inc. is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada. Organigram is focused on producing the highest-quality, condition-specific medical marijuana for patients in Canada. Organigram’s facility is located in Moncton, New Brunswick and the Company is regulated by the Access to Cannabis for Medical Purposes Regulations (“ACMPR”).

This news release contains forward-looking information which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including the availability of funds, consummation of definitive documentation, the results of financing efforts, crop yields – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to put undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE OrganiGram

View original content with multimedia: http://www.newswire.ca/en/releases/archive/June2018/29/c7109.html

Released at Fri, 29 Jun 2018 10:59:20 +0000

Posted in: News

Comments are closed.